LXR agonist increases apoE secretion from HepG2 spheroid, together with an increased production of VLDL and apoE-rich large HDL

Lipids in Health and Disease

Volumn 10, Issue , 2011, Pages

  Kurano, Makoto ^a   Iso O, Naoyuki ^b   Hara, Masumi ^c   Ishizaka, Nobukazu ^a   Moriya, Kyoji ^a   Koike, Kazuhiko ^a   Tsukamoto, Kazuhisa ^a,d  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TEIKYO UNIVERSITY   (Japan)

^d FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

ApoE rich HDL; Apolipoprotein E; LXR agonist; Spheroid HepG2 cells; VLDL

Indexed keywords

ALBUMIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; CELL NUCLEUS RECEPTOR; HIGH DENSITY LIPOPROTEIN; LIVER X RECEPTOR AGONIST; LIVER X RECEPTOR ALPHA; MESSENGER RNA; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; VERY LOW DENSITY LIPOPROTEIN; ALGINIC ACID; APOA1 PROTEIN, HUMAN; FLUORINATED HYDROCARBON; GLUCURONIC ACID; HEXURONIC ACID; HYPOCHOLESTEROLEMIC AGENT; LIVER X RECEPTOR; MICROSPHERE; ORPHAN NUCLEAR RECEPTOR; SULFONAMIDE; TO-901317;

ADIPOCYTE; ARTICLE; CELL STRAIN HEPG2; FAST PROTEIN LIQUID CHROMATOGRAPHY; LIPOGENESIS; MONOLAYER CULTURE; PROTEIN EXPRESSION; PROTEIN SECRETION; SPHEROID CELL; CELL NUCLEUS; CHEMISTRY; CYTOLOGY; DRUG EFFECT; DRUG POTENTIATION; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER CELL; METABOLISM; MULTICELLULAR SPHEROID; OSMOLARITY; PARTICLE SIZE; SECRETION; TIME; UPREGULATION;

ALGINATES; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; CELL NUCLEUS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLUCURONIC ACID; HEP G2 CELLS; HEPATOCYTES; HEXURONIC ACIDS; HUMANS; HYDROCARBONS, FLUORINATED; LIPOPROTEINS, HDL; LIPOPROTEINS, VLDL; MICROSPHERES; ORPHAN NUCLEAR RECEPTORS; OSMOLAR CONCENTRATION; PARTICLE SIZE; RNA, MESSENGER; SPHEROIDS, CELLULAR; SULFONAMIDES; TIME FACTORS; UP-REGULATION;

EID: 79961102521     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-10-134     Document Type: Article

References (30)

1. Apolipoprotein E produced by human monocyte-derived macrophages mediates cholesterol efflux that occurs in the absence of added cholesterol acceptors. Zhang WY, Gaynor PM, Kruth HS, J Biol Chem 1996 271 28641 6 10.1074/jbc.271.45. 28641 8910497 (Pubitemid 26374691)
2. Isoform-dependent cholesterol efflux from macrophages by apolipoprotein E is modulated by cell surface proteoglycans. Hara M, Matsushima T, Satoh H, Iso-o N, Noto H, Togo M, Kimura S, Hashimoto Y, Tsukamoto K, Arterioscler Thromb Vasc Biol 2003 23 269 74 10.1161/01.ATV.0000054199.78458.4B 12588770 (Pubitemid 36231939)
3. Markedly increased secretion of VLDL triglycerides induced by gene transfer of apolipoprotein E isoforms in apoE-deficient mice. Tsukamoto K, Maugeais C, Glick JM, Rader DJ, J Lipid Res 2000 41 253 9 10681409 (Pubitemid 30117866)
4. A far-downstream hepatocyte-specific control region directs expression of the linked human apolipoprotein E and C-I genes in transgenic mice. Simonet WS, Bucay N, Lauer SJ, Taylor JM, J Biol Chem 1993 268 8221 9 7681840 (Pubitemid 23120410)
5. Two hepatic enhancers, HCR.1 and HCR.2, coordinate the liver expression of the entire human apolipoprotein E/C-I/C-IV/C-II gene cluster. Allan CM, Taylor S, Taylor JM, J Biol Chem 1997 272 29113 9 10.1074/jbc.272.46.29113 9360987 (Pubitemid 27498200)
6. Duplicated downstream enhancers control expression of the human apolipoprotein E gene in macrophages and adipose tissue. Shih SJ, Allan C, Grehan S, Tse E, Moran C, Taylor JM, J Biol Chem 2000 275 31567 72 10893248
7. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf DJ, Tontonoz P, Proc Natl Acad Sci USA 2001 98 507 12 10.1073/pnas.021488798 11149950 (Pubitemid 32105072)
8. Apoprotein E biosynthesis in the cholesterol-fed guinea pig. Driscoll DM, Mazzone T, Matsushima T, Getz GS, Arteriosclerosis 1990 10 31 9 10.1161/01.ATV.10.1.31 2297345 (Pubitemid 20035102)
9. Effects of dietary fats and cholesterol on liver lipid content and hepatic apolipoprotein A-I, B, and E and LDL receptor mRNA levels in cebus monkeys. Hennessy LK, Osada J, Ordovas JM, Nicolosi RJ, Stucchi AF, Brousseau ME, Schaefer EJ, J Lipid Res 1992 33 351 60 1314879
10. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, Mangelsdorf DJ, Cell 1998 93 693 704 10.1016/S0092-8674(00)81432-4 9630215 (Pubitemid 28257577)
11. Human hepatocyte cell lines proliferating as cohesive spheroid colonies in alginate markedly upregulate both synthetic and detoxificatory liver function. Khalil M, Shariat-Panahi A, Tootle R, Ryder T, McCloskey P, Roberts E, Hodgson H, Selden C, J Hepatol 2001 34 68 77 11211910 (Pubitemid 32102554)
12. Altered mitochondrial function and cholesterol synthesis influences protein synthesis in extended HepG2 spheroid cultures. Damelin LH, Coward S, Choudhury SF, Chalmers SA, Cox IJ, Robertson NJ, Revial G, Miles M, Tootle R, Hodgson HJ, Selden C, Arch Biochem Biophys 2004 432 167 77 10.1016/j.abb.2004. 09.023 15542055 (Pubitemid 39470013)
13. Liver × receptor inhibits the synthesis and secretion of apolipoprotein A1 by human liver-derived cells. Huuskonen J, Vishnu M, Chau P, Fielding PE, Fielding CJ, Biochemistry 2006 45 15068 74 10.1021/bi061378y 17154544 (Pubitemid 44937019)
14. Induction of apolipoprotein E expression by TR4 orphan nuclear receptor via 5' proximal promoter region. Kim E, Yang Z, Liu NC, Chang C, Biochem Biophys Res Commun 2005 328 85 90 10.1016/j.bbrc.2004.12.146 15670754 (Pubitemid 40164639)
15. Hepatic VLDL assembly is disturbed in a rat model of nonalcoholic fatty liver disease: is there a role for dietary coenzyme Q? Cano A, Ciaffoni F, Safwat GM, Aspichueta P, Ochoa B, Bravo E, Botham KM, J Appl Physiol 2009 107 707 17 19608932
16. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Robertson G, Leclercq I, Farrell GC, Am J Physiol Gastrointest Liver Physiol 2001 281 1135 9 11668021
17. The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. Chisholm JW, Hong J, Mills SA, Lawn RM, J Lipid Res 2003 44 2039 48 10.1194/jlr.M300135-JLR200 12923232 (Pubitemid 37509619)
18. Stimulation of lipogenesis by pharmacological activation of the liver × receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. Grefhorst A, Elzinga BM, Voshol PJ, Plosch T, Kok T, Bloks VW, van der Sluijs FH, Havekes LM, Romijn JA, Verkade HJ, Kuipers F, J Biol Chem 2002 277 34182 90 10.1074/jbc.M204887200 12097330
19. LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms. Verschuren L, de Vries-van der Weij J, Zadelaar S, Kleemann R, Kooistra T, J Lipid Res 2009 50 301 11 18757914
20. Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver × receptor agonist in low-density lipoprotein receptor-deficient mice. Peng D, Hiipakka RA, Dai Q, Guo J, Reardon CA, Getz GS, Liao S, J Pharmacol Exp Ther 2008 327 332 42 10.1124/jpet.108.142687 18723776
21. T-0901317, a synthetic liver × receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. Terasaka N, Hiroshima A, Koieyama T, Ubukata N, Morikawa Y, Nakai D, Inaba T, FEBS Lett 2003 536 6 11 10.1016/S0014-5793(02)03578-0 12586329 (Pubitemid 36206397)
22. Enlargement of high density lipoprotein in mice via liver × receptor activation requires apolipoprotein E and is abolished by cholesteryl ester transfer protein expression. Jiang XC, Beyer TP, Li Z, Liu J, Quan W, Schmidt RJ, Zhang Y, Bensch WR, Eacho PI, Cao G, J Biol Chem 2003 278 49072 8 10.1074/jbc.M304274200 12947111
23. Phospholipid transfer protein is regulated by liver × receptors in vivo. Cao G, Beyer TP, Yang XP, Schmidt RJ, Zhang Y, Bensch WR, Kauffman RF, Gao H, Ryan TP, Liang Y, Eacho PI, Jiang XC, J Biol Chem 2002 277 39561 5 10.1074/jbc.M207187200 12177004 (Pubitemid 35190935)
24. The LXR agonist T0901317 promotes the reverse cholesterol transport from macrophages by increasing plasma efflux potential. Zanotti I, Poti F, Pedrelli M, Favari E, Moleri E, Franceschini G, Calabresi L, Bernini F, J Lipid Res 2008 49 954 60 10.1194/jlr.M700254-JLR200 18252848
25. Selective up-regulation of LXR-regulated genes ABCA1, ABCG1, and APOE in macrophages through increased endogenous synthesis of 24(S),25-epoxycholesterol. Beyea MM, Heslop CL, Sawyez CG, Edwards JY, Markle JG, Hegele RA, Huff MW, J Biol Chem 2007 282 5207 16 17186944 (Pubitemid 47093759)
26. Macrophage liver × receptor is required for antiatherogenic activity of LXR agonists. Levin N, Bischoff ED, Daige CL, Thomas D, Vu CT, Heyman RA, Tangirala RK, Schulman IG, Arterioscler Thromb Vasc Biol 2005 25 135 42 10.1161/01.ATV.0000178996.91277.fb 15539622 (Pubitemid 40054266)
27. Effect of rat plasma high density lipoprotein with or without apolipoprotein E on the cholesterol uptake and on the induction of the corticosteroid biosynthetic pathway in newborn rat adrenocortical cell cultures. Hammami M, Meunier S, Maume G, Gambert P, Maume BF, Biochim Biophys Acta 1991 1094 153 60 10.1016/0167-4889(91)90003-G 1892898
28. Adrenal cholesterol utilization. Kraemer FB, Mol Cell Endocrinol 2007 265-266 42 5 17208360
29. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. Matsuura F, Wang N, Chen W, Jiang XC, Tall AR, J Clin Invest 2006 116 1435 42 10.1172/JCI27602 16670775
30. Structural and functional properties of human plasma high density-sized lipoprotein containing only apoE particles. Krimbou L, Marcil M, Chiba H, Genest J Jr, J Lipid Res 2003 44 884 92 10.1194/jlr.M200273-JLR200 12611904 (Pubitemid 37279648)